AKR1B1 and diabetes mellitus: NSC-94258, as an antineoplastic agent, its protein targets are AKR1B1, CYP19A1, HSD17B1. Aldo-ketoreductase family 1, member B1 (AKR1B1), can prevent complications of diabetes and improve insulin sensitivity by catalyzing the reduction of glucose to sorbitol (Zhan et al., 2019; Syaifie et al., 2022).